UAE conditionally approves new Ultomiris use for immune-mediated kidney disease
The UAE just conditionally approved a new use for Ultomiris for immune-mediated kidney disease, after the prescription was first registered in the UAE in 2022 for the treatment of several rare diseases.The Emirates Drug Establishment (EDE) granted conditional approval for a new indication of AstraZeneca’s Ultomiris (ravulizumab) to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk of disease…



















